SCHEMBL4664341

SCHEMBL4664341

O=CON(c1ccc(Nc2cc(-c3ccc(CCCN4CCOCC4)cc3)ncn2)cc1)S(=O)(=O)c1ccccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 9/20 0.41
BCR P11274 9/20 0.41
JAK1 P23458 4/20 0.39
JAK3 P52333 4/20 0.39
JAK2 O60674 3/20 0.39
BACE1 P56817 1/20 0.38
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
GLA P06280 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663887 0.96 ABL1 (0.41) ABL1BCRJAK1JAK3JAK2
SCHEMBL4666183 0.93 ABL1 (0.42) ABL1BCRJAK1JAK3JAK2
SCHEMBL4664279 0.92 MEN1 (0.39) ABL1BCRJAK1JAK3JAK2
SCHEMBL4664264 0.92 JAK2 (0.41) ABL1BCRJAK1JAK3JAK2
SCHEMBL4665758 0.88 MEN1 (0.40) ABL1BCRJAK1JAK3JAK2
SCHEMBL4666125 0.88 EGFR (0.42) ABL1BCRJAK1JAK3JAK2
SCHEMBL4665661 0.87 BACE1 (0.42) ABL1BCRJAK1JAK3JAK2
SCHEMBL4667497 0.85 ABL1 (0.42) ABL1BCRMEN1USP2ALDH1A1
Formic Acid SCHEMBL4664337 0.84 ABL1 (0.42) ABL1BCRJAK1JAK3JAK2
SCHEMBL4663993 0.84 ABL1 (0.42) ABL1BCRMEN1USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 ABL1 24/4885BCR 402/4885JAK1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.